Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2108 (LINC02108; also known as CTD-2117L12.1) is classified as a long intergenic non-coding RNA (lincRNA), a subclass of long non-coding RNAs (lncRNAs)[1][3]. LincRNAs are defined as RNA transcripts longer than 200 nucleotides that do not overlap with any protein-coding genes[1][3]. They primarily function in the nucleus, where they regulate gene expression through various mechanisms such as chromatin remodeling, transcriptional regulation, and RNA stabilization[1][7]. LincRNAs can also act as scaffolds for protein complexes involved in epigenetic regulation[1][7]. While many lincRNAs have been implicated in various physiological and pathological processes, there is currently no specific evidence that LINC02108 serves as a validated therapeutic target or has direct drug interactions. Its biological and disease relevance, like many lincRNAs, remains an area of ongoing research[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2108 (LINC02108).